{"id":"W4405096087","doi":"10.1182/blood-2024-197902","title":"Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"Pharmacyclics; Genentech; F. Hoffmann-La Roche; Incyte; Constellation Pharmaceuticals; BeiGene; Eli Lilly and Company; AstraZeneca; MorphoSys; Celgene; Gilead Sciences; Agios Pharmaceuticals; Astellas Pharma; TG Therapeutics; Takeda Oncology; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Amgen","keywords":"Mantle cell lymphoma; Refractory (planetary science); Medicine; Safety profile; Lymphoma; Internal medicine; Oncology; Cancer research; Adverse effect; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003325843,0.0002983846,0.0006336845,0.0001583456,0.000250553,0.0003817578,0.0001599601,0.0001934624,0.001253829],"category_scores_gemma":[0.000331685,0.0001271051,0.0002808133,0.0001786731,0.0001823463,0.0002165436,0.0001474865,0.0005821533,0.0004133372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003787108,"about_ca_system_score_gemma":0.0003345244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006788287,"about_ca_topic_score_gemma":0.00249737,"domain_scores_codex":[0.999889,0.00003222782,0.000008759766,0.00002099346,0.00001742648,0.00003162082],"domain_scores_gemma":[0.9998618,0.0000271249,0.0000272606,0.00001283154,0.0000116257,0.00005917784],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1275092,0.01484714,0.171108,0.0006422669,0.0008975144,0.0020482,0.0008773961,0.002993207,0.2696527,0.0001972378,0.006940688,0.4022865],"study_design_scores_gemma":[0.04853219,0.3092668,0.5716733,0.00009545444,0.001067553,0.005813268,0.0003004021,0.006032233,0.03501367,0.0002983758,0.02185721,0.00004958113],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978586,0.0006423268,0.0001924142,0.00005358569,0.000006192491,0.0001471926,0.0001701263,0.0000246476,0.0009048668],"genre_scores_gemma":[0.9982581,0.000377437,0.0003123043,0.0001005728,0.00002053478,0.0001003915,0.0003686873,0.000005731788,0.000456144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001253829,"threshold_uncertainty_score":0.004194498,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005187459901947161,"score_gpt":0.2174212683110892,"score_spread":0.212233808409142,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}